Bracco has invested in Chinese facilities to produce and ship contrast media. The investments are being made through a joint venture with Shanghai-based Sine Pharmaceutical. The Bracco-Sine production plant opened in June in Shanghai's high-tech district. It will focus on the final cycle in contrast media production. Chinese workers will formulate drug solutions from basic ingredients sent from Italy, then prepare, seal, and sterilize individual doses.
Could Virtual Non-Contrast Images from Photon-Counting CT Reduce Radiation Dosing with CCTA?
March 28th 2024Emerging research on coronary artery calcium scoring for the assessment of coronary artery disease (CAD) suggests the use of virtual non-contrast images from photon-counting CT may lead to a nearly 20 percent reduction in radiation dosing.
FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
March 26th 2024The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.